Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL (G104)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03931993
Recruitment Status : Completed
First Posted : April 30, 2019
Last Update Posted : April 30, 2019
Sponsor:
Collaborators:
SynteractHCR
Metronomia Clinical Research GMBH
Information provided by (Responsible Party):
Allergy Therapeutics

Brief Summary:
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of subcutaneous (SC) injections or of sublingual administration. Previously, high cumulative doses of the Grass MATA MPL 10200 and 18200 SU (Standardized Units) were compared with the marketed dose of 5100 SU and were found to have acceptable tolerability and safety. The purpose of this study is to evaluate the tolerability and safety of an even higher cumulative dose regimen of 35600 SU. of Grass MATA MPL compared with placebo in patients with seasonal allergic rhinoconjunctivitis (SAR) due to grass pollen, to enable selection of the best dose to take forward for further development.

Condition or disease Intervention/treatment Phase
Seasonal Allergic Rhinitis Biological: Placebo comparator Biological: Grass MATA MPL Phase 1

Detailed Description:

This will be a placebo-controlled study, using a 1:1 randomization and parallel-group, single-blind design, in patients with seasonal allergic rhino-conjunctivitis to grass pollen conducted at multiple centres in the US. The study will be conducted outside the grass pollen season and is comprised of 3 periods.

  • Period 1: Screening
  • Period 2: Randomization and treatment
  • Period 3: Post-treatment safety follow-up

Period 1 consists of the screening visit (Visit 1) at which patient eligibility will be assessed. Blood samples will be taken for clinical safety laboratory assessments and for baseline transcriptomics analysis. Eligible patients will proceed to Period 2 for enrolment into study.

Period 2 starts with the randomization visit (Visit 2: 3-33 days after Visit 1), at which eligible patients will be randomly allocated to the Grass MATA MPL 35600 SU or placebo treatment groups and receive the first of 6 weekly injections of subcutaneous immunotherapy (SCIT). Injections 2 to 6 will be administered at Visits 3 to 7. After each injection, patients will be kept under observation at the site for at least 30 minutes by personnel qualified to observe for and manage local and systemic adverse events. This period may be extended by the investigator according to his/her judgment. The observation will be followed up by a telephone call approximately 24 hours after the time of injection. In the event of mild or moderate systemic adverse events judged by the investigator to be well-tolerated by the patient and to show good recovery, the patient may continue treatment as scheduled.

Period 3 (Visit 8 - End of Study) will occur 6-8 days after Visit 7 to review any AEs and to perform end-of-treatment assessments, which will include blood draws for safety laboratory tests and transcriptomics analysis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Single-blind
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Pre-Season,Randomized,Single-blind,Placebo-controlled,Parallel-group Study to Determine Tolerability+Safety of a New Cumulative Dose of GrassMATAMPL Compared With Placebo in Patients With Seasonal Allergic Rhinoconjunctivitis Due to Grass Pollen Allergy
Actual Study Start Date : January 16, 2017
Actual Primary Completion Date : April 27, 2017
Actual Study Completion Date : April 27, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hay Fever

Arm Intervention/treatment
Placebo Comparator: Treatment Group 1
Six 1.0mL placebo injections (2% w/v L-tyrosine)
Biological: Placebo comparator
Experimental: Treatment Group 2
Six 1.0mL injections of Grass MATA MPL 900, 2700, 8000, 8000, 8000, and 8000 SU
Biological: Grass MATA MPL



Primary Outcome Measures :
  1. Number and frequency of adverse events (AEs) [ Time Frame: 36 - 48 days ]
  2. Number and frequency of adverse reaction complexes (ARCs) [ Time Frame: 36 - 48 days ]
    The maximum intensity of all injection site [local] and systemic AEs experienced by a patient within a 24-hour period after an injection.

  3. Frequency of premature discontinuation from treatment or study due to AEs. [ Time Frame: 36 - 48 days ]
  4. Changes in vital sign parameters at all visits in the treatment period from pre-injection to post-injection - Systolic blood pressure [ Time Frame: 30 - 40 days ]
    Mean values compared to normal range

  5. Changes in vital sign parameters at all visits in the treatment period from pre-injection to post-injection - Diastolic blood pressure [ Time Frame: 30 - 40 days ]
    Mean values compared to normal range

  6. Changes in vital sign parameters at all visits in the treatment period from pre-injection to post-injection - Pulse [ Time Frame: 30 - 40 days ]
    Mean values compared to normal range

  7. Changes in vital sign parameters at all visits in the treatment period from pre-injection to post-injection - Body temperature [ Time Frame: 30 - 40 days ]
    Mean values compared to normal range

  8. Changes in routine clinical laboratory values - Serum Chemistry [ Time Frame: 36 - 48 days ]
    Absolute and relative number of patients with values below, within or above the normal range

  9. Changes in routine clinical laboratory values - Hematology [ Time Frame: 36 - 48 days ]
    Absolute and relative number of patients with values below, within or above the normal range

  10. Changes in routine clinical laboratory values - Urinalysis [ Time Frame: 36 - 48 days ]
    Absolute and relative number of patients with values below, within or above the normal range

  11. Changes in peak expiratory flow rate (PEFR) before and after injections in asthmatic patients [ Time Frame: 30 - 40 days ]

Secondary Outcome Measures :
  1. Number and frequency of neuro-inflammatory (NI) events. [ Time Frame: 36 - 48 days ]
    Assessed by clinical judgement

  2. Number and frequency of new onset autoimmune disease (NOAD) events. [ Time Frame: 36 - 48 days ]
    Assessed by clinical judgement


Other Outcome Measures:
  1. Transcriptomics analysis [ Time Frame: 36-48 days ]
    X fold-change in expression of selected genes (before and after the treatment)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have a positive skin prick test for grass pollen allergen.
  • Positive skin prick test to positive histamine control
  • Negative skin prick test to negative control
  • Specific IgE for grass pollen as documented by ImmunoCAP test with class ≥ 2
  • A history of moderate to severe symptoms of seasonal allergic rhinitis and/or conjunctivitis due to grass (Pooideae) pollen exposure that required repeated use of antihistamines, nasal steroids, and/or leukotriene modifiers for relief of symptoms during the last two consecutive seasons prior to the study
  • Males or non-pregnant, non-lactating females who are not of child-bearing potential or using effective contraception
  • Patients who are normally active and otherwise judged to be in good health
  • For patients with a history of asthma, forced expiratory volume in 1 second (FEV1) ≥ 80% of National Health and Nutrition Examination Surveys (NHANES) predicted, with a FEV1/forced vital capacity (FVC) ratio ≥ 70%.
  • Able to observe the drug washout times listed in the Prohibited Medications Table below prior to screening
  • Patients willing and able to attend required study visits and able to follow the protocol requirements.
  • Patients willing and able to give written informed consent.

Exclusion Criteria:

  • Symptoms outside the grass pollen season due to a perennial and/or non-grass seasonal allergen, if the patient is unable to avoid the offending allergen.
  • Immunological disorders or other diseases that in the opinion of the investigator may pose a safety risk.
  • Presence of moderate to severe asthma, characterized by the current use of inhaled steroids at a daily dose above 400 micrograms of budesonide (or equivalent)
  • Emergency room visit or admission for asthma in the 12 months prior to Visit 1 or history of a life-threatening asthma attack ever.
  • Presence of non-atopic rhinitis and/or rhino-sinusitis (with or without polyps).
  • Presence of any skin conditions (skin abnormalities, tattoos etc.) which might interfere with the interpretation of the SPT results.
  • Current diagnosis of type I diabetes. Patients with type II diabetes will only be allowed to participate at the discretion of the investigator.
  • Treatment with a preparation containing MPL (e.g. Cervarix) within 6 months prior to screening
  • Moderate to severe upper or lower respiratory tract infections requiring medication within 14 days of or a diagnosis of sinusitis within 30 days of randomisation
  • Clinical history of severe or life-threatening anaphylactic reactions to foods, insect venom, exercise, drugs or idiopathic anaphylaxis.
  • Clinical history of allergy, hypersensitivity or intolerance to the excipients of the study medication.
  • Tyrosine metabolism disorders, especially tyrosinemia and alkaptonuria.
  • Unable to receive epinephrine therapy (i.e., use of epinephrine is contraindicated).
  • Clinical history of immunodeficiency, including those who are on immunosuppressant therapy.
  • Clinical history of recurrent idiopathic angioedema.
  • Beta-blocker medication, including eye drops, for any indication.
  • Treatment with monoamine oxidase inhibitors, tricyclic antidepressants or ACE inhibitors.
  • Clinical history of drug or alcohol abuse which, in the investigator's opinion, could interfere with the patient's ability to participate in the study.
  • Participation in a clinical research trial with any investigational medicinal product within 4 weeks of screening or concomitantly with this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03931993


Locations
Layout table for location information
United States, New Jersey
Vedas Research
Edison, New Jersey, United States
Atlantic Reseach Center
Ocean City, New Jersey, United States, 07712
STARx Asthma and Allergy Center
Springfield, New Jersey, United States, 07081-2515
Allergy Partners of New Jersey
Teaneck, New Jersey, United States
Sponsors and Collaborators
Allergy Therapeutics
SynteractHCR
Metronomia Clinical Research GMBH
Investigators
Layout table for investigator information
Study Director: Tim Higenbottam, MD, FRCP Allergy Therapeutics
Layout table for additonal information
Responsible Party: Allergy Therapeutics
ClinicalTrials.gov Identifier: NCT03931993    
Other Study ID Numbers: GrassMATAMPL104
First Posted: April 30, 2019    Key Record Dates
Last Update Posted: April 30, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Allergy Therapeutics:
Grass MATA MPL
Safety
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases